User login
Key clinical point: In patients with hepatocellular carcinoma (HCC), transarterial radioembolization (TARE) provides significantly longer time to progression (TTP) than transarterial chemoembolization (TACE), but does not significantly prolong overall survival.
Major finding: TARE vs TACE significantly prolonged the mean TTP (17.5 vs 9.8 months; 95% CI 1.3-8.3 months) but resulted in comparable overall survival (absolute difference −0.55 months; 95% CI −1.95 to 3.05 months).
Study details: This was a meta-analysis of 17 studies involving 2465 unique patients that directly compared TACE and TARE for treating HCC.
Disclosures: This study was supported by the US National Institutes of Health. Some authors declared serving as consultants or advisory board members of or receiving grants from various sources.
Source: Brown AM et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta-analysis. Cancer Med. 2022 (Aug 9). Doi: 10.1002/cam4.5125
Key clinical point: In patients with hepatocellular carcinoma (HCC), transarterial radioembolization (TARE) provides significantly longer time to progression (TTP) than transarterial chemoembolization (TACE), but does not significantly prolong overall survival.
Major finding: TARE vs TACE significantly prolonged the mean TTP (17.5 vs 9.8 months; 95% CI 1.3-8.3 months) but resulted in comparable overall survival (absolute difference −0.55 months; 95% CI −1.95 to 3.05 months).
Study details: This was a meta-analysis of 17 studies involving 2465 unique patients that directly compared TACE and TARE for treating HCC.
Disclosures: This study was supported by the US National Institutes of Health. Some authors declared serving as consultants or advisory board members of or receiving grants from various sources.
Source: Brown AM et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta-analysis. Cancer Med. 2022 (Aug 9). Doi: 10.1002/cam4.5125
Key clinical point: In patients with hepatocellular carcinoma (HCC), transarterial radioembolization (TARE) provides significantly longer time to progression (TTP) than transarterial chemoembolization (TACE), but does not significantly prolong overall survival.
Major finding: TARE vs TACE significantly prolonged the mean TTP (17.5 vs 9.8 months; 95% CI 1.3-8.3 months) but resulted in comparable overall survival (absolute difference −0.55 months; 95% CI −1.95 to 3.05 months).
Study details: This was a meta-analysis of 17 studies involving 2465 unique patients that directly compared TACE and TARE for treating HCC.
Disclosures: This study was supported by the US National Institutes of Health. Some authors declared serving as consultants or advisory board members of or receiving grants from various sources.
Source: Brown AM et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta-analysis. Cancer Med. 2022 (Aug 9). Doi: 10.1002/cam4.5125